Related Experiment Videos
RARA and PML genes in acute promyelocytic leukemia
Abstract:
Acute promyelocytic leukemia (APL) is characterized by a specific chromosome translocation t(15;17). Recently, using molecular biology techniques, a number of laboratories have demonstrated that the gene coding for the retinoic acid receptor alpha (RARA), normally located on chromosome 17, is disrupted by the t(15;17) and fused with the PML gene on chromosome 15. The chromosome 17 breaks were mapped consistently within the second intron of the RARA gene while the chromosome 15 breaks were clustered in two limited regions within the PML gene. Molecular cloning and sequence analysis of the PML gene demonstrated a complex splicing pattern and this gene may encode a transcription factor. Different isoforms of the PML-RARA fusion transcripts were discovered which are produced as a result of distinct PML gene rearrangements. Sequence analysis of the reciprocal products of the translocation t(15;17) in some APL cases suggested the implication of topoisomerase II in mediating the DNA recombination. The RT/PCR procedure has been established to characterize the expression patterns of the PML-RARA fusion gene and to detect minimal residual disease (MRD). The biological activity of the PML-RARA fusion gene and its isoforms should be further explored.
Insights
Acute promyelocytic leukemia (APL) involves the t(15;17) translocation, fusing the retinoic acid receptor alpha (RARA) and PML genes. This fusion creates PML-RARA transcripts, detectable by RT/PCR for monitoring minimal residual disease.
Area of Science:
- Molecular biology
- Genetics
- Hematology
Background:
- Acute promyelocytic leukemia (APL) is defined by the t(15;17) chromosome translocation.
- The retinoic acid receptor alpha (RARA) gene on chromosome 17 fuses with the PML gene on chromosome 15 due to this translocation.
- The PML gene may encode a transcription factor with a complex splicing pattern.
Purpose of the Study:
- To investigate the molecular mechanisms of the t(15;17) translocation in APL.
- To characterize the PML-RARA fusion gene and its different isoforms.
- To establish methods for detecting minimal residual disease (MRD) in APL patients.
Main Methods:
- Molecular cloning and sequence analysis of the PML gene.
- Reverse Transcription Polymerase Chain Reaction (RT/PCR) to analyze PML-RARA fusion gene expression.
- Mapping of chromosome breaks within RARA and PML genes.
Main Results:
- The t(15;17) translocation consistently disrupts the RARA gene within its second intron and clusters breaks in specific PML gene regions.
- Multiple isoforms of the PML-RARA fusion transcript result from distinct PML gene rearrangements.
- RT/PCR successfully characterizes PML-RARA expression patterns and detects MRD.
Conclusions:
- The PML-RARA fusion gene is a key molecular characteristic of APL.
- The biological activity of PML-RARA isoforms warrants further investigation.
- RT/PCR is a valuable tool for MRD detection in APL.